Sensyne Health PLC's (LON:SENS) Chief Executive Lord Paul Drayson talks to Proactive London's Katie Pilbeam about their latest 'breakthrough deal' with Excalibur.
The firm has signed a COVID-19 test partnership as part of an exclusive licence and development agreement with Excalibur Healthcare Services.
Drayson explains that it is the 'first time the company have secured a recurring revenue royalty deal on the sales of someone else's product in exchange for providing the artificial intelligence inside that makes their products perform better'.